NCT03986086 2020-03-20MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell TransplantationDuke UniversityPhase 1/2 Withdrawn
NCT02223312 2018-08-28Therapy for Progressive and/or Refractory Hematologic MalignanciesKiromic BioPharma Inc.Phase 1/2 Withdrawn
NCT01163201 2017-12-02T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesMasonic Cancer Center, University of MinnesotaPhase 1/2 Withdrawn
NCT01326273 2015-06-08Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV ReactivationImperial College LondonPhase 1/2 Withdrawn
NCT01620229 2014-04-21Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesFred Hutchinson Cancer CenterPhase 1/2 Withdrawn